VJHemOnc is committed to improving our service to you

ASH 2019 | CPX-351 shows promising results in poor risk AML (t-AML and MRC-AML)

VJHemOnc is committed to improving our service to you

Thomas Cluzeau

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses a report from a multicentric French cohort. This study analyzed the efficacy of a liposomal formulation of cytarabine and daunorubicin (CPX-351) in a real-life setting in patients with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). Prof. Cluzeau highlights the excellent results, confirming the efficacy and safety of CPX-351, including in patients with unfavorable mutations. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter